ACE and chronic kidney disease: ACE inhibitors and ARBs play a foundational role, particularly in patients with albuminuria, due to their dual benefits in lowering BP and mitigating glomerular injury, thereby slowing CKD progression and reducing cardiovascular risk [1-5].